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Introduction 
Endometriosis affects approximately 3% of women of reproductive age. 
The term endometriosis is applied to a condition where actively 
functioning endometrium is found in ectopic situations other than lining 
the uterine cavity, such as bladder, ovaries, intestines. This tissue 
responds to monthly cyclical hormonal changes and has no means of 
escaping the body when it has broken down. While normal endometrium 
is expelled as menstrual bleeding, ectopic endometrial tissue remains in 
the body causing inflammation, pelvic pain, abnormal menstruation and 
infertility. If left untreated, the condition becomes worse. 
Current evidence suggests that menstrual relfux into the pelvis and the 
secretion of oestrogen are central to the pathogenesis of endometriosis. 
Menstrual reflux could be affected by contraceptive use, decreasing 
parity, delay in attempting pregnancy, tubal occlusion and the use of 
tampons. 
Conservative treatment involves the use of hormonal agents, including 
oestrogen-progesterone preparations and progesterone-only regimens for a 
pseudopregnancy effect, whilst GnRH agonsists and danazol induce a 
pseudopregnancy effect. 
This study aims at investigating the incidence of endometriosis in 
Maltese women, what drugs are being used to treat this condition, and 
what are the main side-effects being experienced. All the above 
mentioned preparations for endometriosis are available at 5t. Luke's 
Hospital, with the exception of the GnRH-a. 
Methodology 
Surveyl 
Retrospective Study 
a) 'The files of all women who underwent a laparoscopy at Karin 
Grech Theatre during 1990 were screened for any cases of 
endometriosis. 
b) The number of patients to whom danazol was prescribed during 
the year 1990 was obtained from records at the Pharmacy Unit. 
These patients' files were also screened. 
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All files were obtained through the Gynae Outpatient's Department. 
The following information was retrieved: 
i ) the incidence of endometriosis in Maltese women 
i i ) the most common age group in which endometriosis occurred 
i i i) the most common symptoms associated with this disease 
i v ) the extent of disease 
v) menstrual cycle patterns 
vi) whether a correlation existed between endometriosis of a delay 
in attempting pregnancy 
vii) what drugs were being used to treat the condition 
Survey 2 
Patients receiving Danazol treatment 
Twenty patients treated with danazol for a duration of 3 - 6 months 
obtained their medication free of charge from the St. Luke's Hospital 
pharmacy on a monthly basis between July and December 1991. When the 
patients visited the hospital pharmacy to collect their medication, they 
were interviewed and the results compiled on a questionnaire format. 
The patients were mainly asked about their presenting complaint which 
led to the diagnosis of endometriosis and whether there were any 
experiences of adverse effects. The patients were also asked whether 
they were given any information about their condition and whether they 
were satisfied or felt the need to know more. 
Survey 3 
Gynaecologists' views on the drugs used for Endometriosis 
Questionnaires were sent to twenty gynaecologists working at St. Luke's 
Hospital. It was attempted to investigate their views on the drug 
treatment of endometriosis, whether they are satisfied with the drugs 
available in hospital, or whether they would rather prescribe some 
alternative form of therapy. 
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Results 
Survey 1 
A total of 50 files were screened: 40 patients were recorded to have been 
prescribed danazol during 1990; 10 patients were diagnosed as having 
endometriosis by laparoscopy. 
The modal age group in which endometriosis occurred was between 31 - 35 
years (n=13), and up to 5 years before and after this age bracket [(n=12) 
and (n=l1) respectively]. Only 1 patient over 50 years of age had 
endometriosis. 
The majority of patients had their first period at 11 - 12 years of age 
(n=21). Equal numbers of patients (n=21) suffered mild and moderate 
losses, whilst pain was ):llild in 52% (n=26) of the patients. Menstruation 
tended to last for 5 - 7 days in the majority of patients (44%, n=22). 
10% (n=5) of the women studied were single, eighteen patients had 
children and 8 of those who became pregnant experienced miscarriages. 
The modal age group at first pregnancy was between 26 - 30 years. 
Table 1: Most common symptoms associated with Endometriosis 
Number of patients 
Presenting Total 1st 2nd 
complaint complaint complaint 
Infertili ty 31 (62%) 27 4 
Dysmenorrhoea 9 (18%) 4 5 
~elvic pain 15 (30%) 12 3 
Dyspareumia 8 (16%) 1 7 
Nausea 5 (10%) 5 
Spotting 4 (8%) 2 2 
Menorrhagia 4(8%) 2 2 
Other* 5 (10%) 2 3 
* include pain on micturition, recurrent abortions, ovulation pain 
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Approximately 52% (n=27) suffered from only one symptom whilst 46% 
(n=23) experienced more than one symptom. 40% (n=20) had moderate 
endometriosis, whilst 20% (n=6) had extensive endometriosis. 
The most frequently used regimen for danazol was 200mg tds, 75% (n=32), 
for a total of 6 months, 73% (n=29). Adjunct therapy was used in two 
cases. 
Table 2: Drugs employed in the treatment of Endometriosis 
Number of 
Patients 
Danazol Progestogens 
40 7 
Ovulatory None 
1 2 
The most frequently used regImen for danazol was 200mg tds, 75% (n=32), 
for a total of 6 months, 73% (n=29). Adjunct therapy was used in two 
cases. 
Table 3: Outcome of Danazol Ther8py 
Effect 
Breakthro' bleeding 
ChangedRx 
Increased dose 
Decreased dose 
Rx stopped 
Became pregnant 
Delivered 
Number of Patients 
12 
1 
4 
1 
4 
3 
2 
The dose of danazol had to be increased in 4 patients (8%) due to 
breakthrough bleeding which occurred in 24% (n=12). Four patients 
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stopped danazol Rx before the stipulated date, one of which was found to 
be allergic to danazol. 
Survey 2 
Most of the twenty women interviewed with endometriosis were aged 
between 31 - 40 years (n=11), followed by 26 - 30 years (n=7). 
Half of the patients had a 200mg tds regimen and the remainder 200mg 
qid. The duration of therapy was 6 months for 18 patients and 3 months 
for 2 patients. Nineteen patients were prescribed danazol for the first 
time, whilst one patient was taking danazol on a repeat prescription. 
19 patients claimed to be experiencing side-effects, whilst one patient did 
not. 80% of patients experienced more than one side-effect. Half of the 
patients experienced breakthrough bleeding, which persisted in all the 6 
cases where the dose was increased. 
Table 4: Commonest side-effects experienced with Danazol 
Side-effect experienced 
Hot flushes 
Breakthrough bleeding 
Back pain 
Bloatedness 
Weight gain 
Acne 
Hirsutism 
Number of patients 
13 
11 
6 
6 
4 
2 
1 
All patients were given information about endometriosis either by a 
consultant (80% [n=16]), or by someone else (20% [n=4]). Only one patient 
was given a leaflet in addition to verbal advice. 85% (n=17) of the 
women felt that they were satisfied with the information given, whilst 
15% (n=3) felt the need to know more. Although most patients were 
informed about their condition, they claimed that they had no written 
literature to refer to, especially concerning the side-effects of their drug 
therapy. The drug was in fact dispensed from the pharmacy without any 
accompanying package information. 
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Survey 3 
3 senior house officers, 4 consultants and 6 senior assistants responded, 
making up a 65% response (n=13) rate. 
According to them, the most common primary symptoms associated with 
endometriosis are dysmenorrhoea (n=7), followed closely by infertility 
(n=6) and dyspareunia (n=1). The commonest age groups were between 26-
30 years (n=7) and between 31 - 40 years (n=6). 
Eight gynaecologists claimed that they use danazol as the first drug of 
choice. 2 of these said that they would use GnRH-a as a second-line drug. 
Progesterone-only regimens were favoured by 2 doctors, GnRH-a by one 
and another claimed to have no drug of choice. 
Reasons for choosing danazol included the fact that it is less expensive 
than some forms of therapy, is quite effective especially for treating 
infertility and that it is relatively free from side-effects. Others use 
danazol because they have more experience with this drug. In the case of 
a few Senior House Officers or Senior Assistants, the drug was used 
because it was prescribed by the consultant. Only 5 out of 12 
gynaecologists said that danazol gave rise to serious side-effects. All but 
one agreed that GnRH-a will be used in the future and only 2 disagreed 
that the expense would be justified. However, this would depend on 
whether the drug is available through hospital services. 5 
gynaecologists stated that laser laparoscopy would supercede drug 
therapy. 
Conclusion 
The first survey concludes that endometriosis seems to affect 0.07% of the 
Maltese women population and are principally aged between 31 to 40 
years. The incidence in Maltese women is much lower than the 1 - 5% 
incidence rate reported in other studies. 
The most common symptoms associated with endometriosis was 
infertility at a rate higher than that estimated by some reports, whilst 
the percentage of women suffering from dysmenorrhoea was lower. The 
percentage of women experiencing dyspareumia and menstrual 
irregularities seemed to be within ranges estimated in some 
investigations. 
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The most popular drug used in treating endometriosis was danazol, but 
Survey 2 concluded that its use was related to a number of adverse effects, 
namely breakthrough bleeding and hot flushes. Although most adverse 
effects are unavoidable and often of minor importance, they will 
certainly affect the quality of the patients' lives, especially when more 
than one adverse effect is experienced. 
In general, the gynaecologists' view on medical treatment with danazol 
(as concluded in the third survey), is speculative. It has a limited role, 
especially since it is difficult to optimise treatment with a limited 
choice of drugs. Some gynaecologists claim that medical treatment is 
ineffective for pain with little effect in improving fertility, preventing 
recurrence of endometriosis or long-term sequelae of the disease. One also 
has to balance long-term treatment and the delay in trying to conceive in 
patients suffering from infertility. Some suggest that only mild to 
moderate cases should be treated and these should be closely followed 
with repeat laparoscopies and monitoring of side-effects. 
Only exceptionally few cases of endometriosis were given a classification 
of the extent of their disease. Some sort of survey sheet classifying the 
various stages of endometriosis should be introduced. A suggested format 
is that used by the American Fertility Society Revised Classification of 
Endometriosis. 
Pharmacists can help by monitoring the patients' progress when they 
attend the pharmacy for repeat prescriptions. They should enforce any 
information given, especially on the issue of physical methods of 
contraception during danazol use, and making sure that they comply with 
the drug regimen. The latter may be difficult for some patients who do 
not feel that they. know enough about the drugs that they are taking. 
Thus, as part of this dissertation, an attempt has been made to compile 
concise information about endometriosis and danazol in the form of a 
handy leaflet, and distributing these leaflets to danazol patients at the 
Out Patients' Dispensary at St. Luke's Hospital. 
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